Feb 8 (Reuters) - Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shinjini Ganguli)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Retirement savings play a crucial role in securing financial stability in your golden years. For those aiming high, being in the top 3% of retirees in terms of savings enhances comfort and offers greater financial freedom. Using data from the Federal Reserve's Survey of Consumer Finances, a 2024 survey by the Employee Benefit Research Institute, reveals that individuals with over $1 million in retirement accounts rank in the top 3% of retirees. Only 3.2% of retirees have surpassed the $1 million
The $50 million purchase could turn into Nvidia's biggest investment.
These proven wealth builders could be exactly what you're searching for right now.
$10,000 to each of these companies could deliver major returns over the next decade.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
You'll get dividends and more with these great stocks.
There are benefits to investing in stocks that have reasonable multiples and aren't as dependent on future earnings growth to justify their valuations.
The number probably isn't anywhere near what you think it is.